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Hypereosinophilic syndrome (HES) is a heterogeneous group of hematological disorders characterized by a chronic,
unexplained hypereosinophilia with tissue damage. Cardiac involvement occurs in 20% of patients with HES and
represents a major turning point. Cardiac injuries related to eosinophilia are divided into three chronological phases:
eosinophilic infiltration, thrombosis, and fibrosis. We report a case of a 33-year-old woman diagnosed with HES, with
pulmonary and gastrointestinal involvement and eosinophilic myocarditis in cardiogenic shock. The evolution was
favorable with dobutamine, anticoagulation, corticosteroids, and later, b-blockers and angiotensin-converting enzyme
inhibitors. Cardiac involvement in HES is rare but carries a poor prognosis. Corticosteroids are considered by many to
be the mainstay of treatment. Although new treatments have been suggested, only a few seem promising.
 2016 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Hypereosinophilic syndrome (HES) is aheterogeneous group of hematological dis-
orders characterized by chronic, unexplained
hypereosinophilia with tissue damage [1]. Cardiac
involvement occurs in 20% of patients with HES
and represents a major turning point [2]. Cardiac
injuries related to eosinophilia are divided into
three chronological phases: eosinophilic infiltra-
tion and myocarditis, thrombosis, and fibrosis.
Although major diagnostic and therapeutic
advances have been made, HES remains under-
recognized and has a poor prognosis [3].Case report
A 33-year-old woman, with no relevant medical
history but a chronic cough, was admitted to our
hospital for abdominal pain and vomiting. On
admission, vital signs were normal: blood pres-
sure: 125/68 mmHg, heart rate: 75 beats/min, res-
piratory rate: 18 breaths/min, body temperature:
36.7 C. Physical examination was normal besides
abdominal tenderness. Thoracic and abdominal
computed tomography was performed showing
interstitial lung disease and thickening of the gas-
tric antrum walls, along with intestinal dilatation
(Fig. 1). Esophagogastroduodenoscopy revealed
antritis. During the procedure, multiple gastriceCCBY-
, http://
Figure 1. Abdominal computed tomography showing an important
thickening of the gastric antrum walls (arrow) along with an
intestinal dilatation.
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matory lesions with eosinophil infiltration. Labo-
ratory tests revealed elevated levels of eosinophil
cell count (>2925/mm3), C-reactive protein
(86 mg/l), and immunoglobulin E (>1677 ng/mL).
Antineutrophil cytoplasmic antibody and antinu-
clear antibodies were negative. Bone marrow aspi-
ration found rich marrow filled with eosinophilic
myelocytes and mature eosinophils. During her
hospital stay, the patient developed shock. Elec-
trocardiography showed atrial fibrillation along
with nonspecific T-wave and ST changes on infe-
rior and anterolateral leads. Troponins were posi-
tive. Transthoracic echocardiography (TTE)
demonstrated dilated cardiac cavities with severe
global left ventricular (LV) systolic dysfunction
(LV ejection fraction = 29%; Fig. 2). Coronary
angiography was normal. In view of the patient’s
clinical, biological, radiological, and histological
findings, we decided that eosinophil myocarditisFigure 2. Transthoracic echocardiography: an apical four-chamber
view showing a severe impairment of the left ventricular ejection
fraction.
Please cite this article in press as: Boussir H. et al., Eosinophilic myocarditi
dx.doi.org/10.1016/j.jsha.2016.11.001(EM) was the cause of the cardiogenic shock. Ini-
tially, the patient received dobutamine, anticoagu-
lants, and corticosteroids in the intensive care
unit. After improvement of the hemodynamic sta-
tus, b-blockers and angiotensin-converting
enzyme inhibitors were started and uptitrated to
12.5 mg carvedilol twice daily and 5 mg/d ramipril.
Control transthoracic echocardiography showed
significant LV systolic function improvement (LV
ejection fraction: 45%).Discussion
Eosinophilic cardiac disease is a rare condition
that was first described in 1936 by Wilhelm
Löffler, who called it ‘‘fibroplastic parietal endo-
carditis with blood eosinophilia’’; also known as
Löffler’s endocarditis [2]. Cardiac injuries related
to eosinophilia are divided into three chronologi-
cal phases: eosinophilic infiltration, as in our
patient, thrombosis, and fibrosis. The first stage
is characterized by EM with eosinophil and lym-
phocyte infiltration [1]. The myocardial damage
is due to the release by eosinophils of cationic pro-
teins capable of inducing necrosis and apoptosis,
namely, major basic protein, eosinophil cationic
protein, eosinophil-derived neurotoxin, and eosi-
nophil peroxidase [2].
Several diseases may be responsible for eosino-
philia such as drugs, infections, allergies, systemic
diseases, malignancies, and HES [1,2]. Our patient
had not been taking any medication. No personal
or familial allergies were known. After a thorough
history taking, physical examination, and oriented
workup, we concluded that she had HES.
HES has been defined by Chusid et al. [4] as
eosinophilia >1500/mm3 for >6 months, without
any secondary cause and with evidence of tissue
damage [4]. It is more common between 20 years
and 50 years of age and in men [5]. Two subtypes
of HES must be recognized: a lymphocytic variant
(L-HES) and a myeloproliferative one. Bone mar-
row cytogenetic analysis and fluorescent in-situ
hybridization are mandatory for their diagnosis.
The L-HES variant is characterized by an increase
in cytokine production, notably interleukin (IL)-5,
that plays an essential role in eosinophil produc-
tion, survival, chemotaxis, and degranulation.
The mainstream treatment for L-HES variant is
corticosteroids. In the majority of myeloprolifera-
tive variant patients, a fusion gene, namely
FIP1L1-PDGFRA (FP), is found. The FP gene is
responsible for the production of an active
protein-tyrosine kinase capable of transforming
hematopoietic cells into eosinophil precursors,s and hypereosinophilic syndrome, J Saudi Heart Assoc (2016), http://
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respond well to imatinib (a tyrosine kinase inhibi-
tor) [1]. Although dermatological, pulmonary, and
gastrointestinal involvement seems to be more
frequent, cardiac injury is the most redoubtable
as it is the major source of morbidity and mortality
[6]. Our patient had eosinophilic antritis, intersti-
tial lung disease, and myocarditis. EM may mani-
fest in many forms, ranging from patients without
any cardiac complaints to cardiogenic shock, as in
the case of our patient. However, it is noteworthy
that most patients report an influenza-like syn-
drome prior to the onset of EM [2]. Electrocardio-
graphy usually shows nonspecific ST/T
abnormalities and sometimes an S1Q3 aspect
[2,3]. Echocardiography is a useful and broadly
available tool in assessing patients with EM
because it helps to rule out differential diagnosis,
but also evaluate and monitor cardiac chamber
size, wall thickness, ventricular systolic, and dias-
tolic function, and to detect the presence of peri-
cardial effusion. Cardiac magnetic resonance is
currently the gold standard in noninvasive diag-
nosis of myocarditis [2,7]; however, it remains
more often than not burdensome due to its high
cost and low availability, especially in developing
countries. Endomyocardial biopsy is the only
method to definitely make the diagnosis of EM
[2]. We did not perform a biopsy because we
had all the data that we needed to establish the
diagnosis.
Patients with EM manifesting with heart failure
or arrhythmias are managed according to current
guidelines. Specific treatment of EM is under-
taken according to its underlying etiology. In
patients with HES, it depends on the variants. In
the L-HES variant, corticosteroids, although being
controversial, are the first line of treatment. In
case of resistance, anti-IL-5 (mepolizumab) is rec-
ommended. For the myeloproliferative variants,
as explained earlier, imatinib should be initiated
[8]. A flood of new treatments for eosinophilic
disorders have been suggested but only a few—
receptors like benralizumab representing a
humanized antibody to IL-5 receptor-a—seemPlease cite this article in press as: Boussir H. et al., Eosinophilic myocarditi
dx.doi.org/10.1016/j.jsha.2016.11.001promising [9]. Unfortunately, they have a shortage
of evidence from randomized trials.
In conclusion, cardiac involvement in hypere-
osinophilia, although rare, carries a poor progno-
sis. It ranges from asymptomatic myocarditis to
fibrotic scarring through cardiogenic shock and
thromboembolic complications. All etiologies
must be ruled out before establishing the diagno-
sis of HES. Early detection and treatment of
myocardial involvement improves prognosis. On
this basis, echocardiography must be practiced
in moderate (1500/mm3) to severe eosinophilia
(>5000/mm3) [7]. Specific treatment of EM is
undertaken according to its underlying etiology.
Immunosuppressive therapy represents the core
treatment in the majority of patients with EM.
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